Lessons learned from the gene therapy trial for ornithine transcarbamylase deficiency

It has been 9 years since Mr. Jesse Gelsinger died from complications of vector administration in a liver gene therapy trial of research subjects with a deficiency of ornithine transcarbamylase (OTCD). This study was performed at the Institute for Human Gene Therapy of the University of Pennsylvania...

Full description

Saved in:
Bibliographic Details
Published in:Molecular genetics and metabolism 2009-04, Vol.96 (4), p.151-157
Main Author: Wilson, James M.
Format: Article
Language:English
Subjects:
Clinical trial
Clinical Trials as Topic
Clinical Trials, Phase I as Topic
Gene therapy
Genetic Therapy
Humans
Ornithine Carbamoyltransferase Deficiency Disease - genetics
Ornithine Carbamoyltransferase Deficiency Disease - therapy
Ornithine transcarbamylase deficiency
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:It has been 9 years since Mr. Jesse Gelsinger died from complications of vector administration in a liver gene therapy trial of research subjects with a deficiency of ornithine transcarbamylase (OTCD). This study was performed at the Institute for Human Gene Therapy of the University of Pennsylvania (Penn) which I directed. His tragic death provoked a series of events that had implications beyond those directly involved in the clinical trial. The events surrounding the death of this research subject have been the topic of much coverage and commentary in the popular press. The goal of this article is to share with you my reflections on the OTCD gene therapy trial and lessons that I have learned which may be of value to others engaged in various aspects of translational medicine.
ISSN:1096-7192
1096-7206
DOI:10.1016/j.ymgme.2008.12.016